According to Swedish CRO Medicon Valley Inhalation Consortium (MVIC), the organization has entered into a 2-year, €1.6 million contract with a Chinese company to develop an inhaled generic drug for the treatment of asthma and COPD. MVIC will develop a new inhalation product for asthma and COPD. The new contract brings MVIC’s total orders over the past year to €2.5 million.
The consortium recently added four new member companies. In addition to providing development services for inhalation products, MVIC also sponsors the Medicon Valley Inhalation Symposium.
